To determine whether the frequency of Parkinson disease (PD), dementia, and vascular diseases in relatives of patients with amyotrophic lateral sclerosis (ALS) differs from the frequency of those diseases in relatives of controls, providing further information about the association between these diseases.
The discovery of the ALS-Parkinson-dementia complex on the Island of Guam 1 and the observation that nearly half of the patients with ALS have cognitive impairment, as revealed by extensive neuropsychological testing, indicate that ALS may share pathophysiologic pathways with other neurodegenerative diseases. 2, 3 The frequency of neurodegenerative diseases among relatives of patients with ALS has been investigated in often non-population-based studies (table 1). 4 -9 Due to the variation in results of these studies, doubt remains whether relatives have an increased risk of neurodegenerative diseases, suggesting shared genetic or environmental risk factors.
Case-control studies have shown that vascular diseases occur less frequently in patients with ALS, 10 that dyslipidemia prolongs survival, 11 that patients use cholesterol-lowering medication less often, 12 have a lower premorbid body mass index (BMI), 12, 13 and have a favorable lipid profile. 12 These results suggest that a beneficial vascular risk profile is associated with ALS. However, smoking 14 -18 and a low intake of polyunsaturated fatty acids, 19 both well-known vascular risk factors, may be associated with an increased risk of ALS. Occurrence of vascular diseases in relatives of patients with ALS could provide further information about the role of the vascular risk profile in ALS susceptibility. The family history of vascular diseases in patients with ALS has, however, never been studied before.
The aim of our population-based study was to determine whether the occurrence of ALS, PD, dementia, and vascular diseases in relatives of patients with ALS differs from the occurrence in relatives of controls.
METHODS Study population. We conducted a population-based, case-control study in the Netherlands between January 1, 2006, and May 31, 2009 , entitled the Prospective ALS study in the Netherlands (PAN). The Netherlands is a densely populated country, located in northwest Europe. The mean population during the study period was 16,421,357. 20 Participants. All newly diagnosed patients and all patients diagnosed before January 2006 and still alive on January 1, 2006, were selected. Patients were diagnosed as possible, probable (laboratory-supported), or definite ALS according to the revised El Escorial criteria. 21 Medical records of all patients were examined to confirm the appropriateness of the diagnosis and to exclude ALS mimic syndromes or other clinical conditions. Every patient who had a first-, second-, or third-degree family member with ALS was defined as having familial ALS (FALS).
Use was made of multiple sources to ensure complete ascertainment: 1) Neurologists. Most patients with ALS in the Netherlands visit one of the tertiary referral centers of the ALS center the Netherlands on at least one occasion. All these patients were asked to participate. Neurologists in other hospitals were visited or contacted at least every year with a view to collecting all patients with ALS. 2) Consultants in rehabilitation medicine. There are 26 specialized ALS rehabilitation centers, which were visited or contacted by telephone at least once per year. Consultants in other rehabilitation centers were informed annually by mail about the study. 3) The Dutch Neuromuscular Patient Association. Once per year, members of this association were invited to participate. 4) Internet. Patients were able to register themselves via our Web site.
Population-based controls were selected from the register of the general practitioner (GP) taking care of the patient with ALS. (The Dutch health care system ensures that everyone is registered with a GP.) The GP was asked to select the first 3 patients from the alphabetical register who met the criteria, starting with the surname following the name of the patient with ALS. Controls should be of the same sex and age, plus or minus 5 years. Spouses or blood relatives of the patient were excluded to prevent overmatching.
Standard protocol approvals, registrations, and patient consents. Ethics approval was provided by the institutional review board of the University Medical Center Utrecht. All participants gave written informed consent.
Data ascertainment. In order to obtain family history data, patients and controls were asked to fill in structured questionnaires. For each parent, grandparent, aunt, uncle, and sibling, they were asked to state whether the specific family member had been diagnosed with ALS, dementia, PD, stroke, or myocardial infarction (MI). Participants (both patients and controls) who returned questionnaires were contacted to confirm and complete data.
Statistical analysis. Baseline characteristics were tested for differences using Pearson 2 and the independent samples t test. All patients with ALS, both sporadic and familial, and all controls were included to determine the aggregation of ALS. Sepa- Table 1 Characteristics of studies on the family history in ALS rate analyses were performed on patients with sporadic ALS (SALS) and FALS to compare the risk of dementia, PD, stroke, and MI in relatives of patients and controls. Patients with SALS were compared with controls who did not have a family member with ALS; patients with FALS were compared with all controls. Only relatives with a known disease status were included in the analysis. The observed rate of disease among relatives of patients with ALS and controls was used to obtain a risk ratio, , calculated by dividing the rate of disease among relatives of patients with ALS by the rate of disease among relatives of controls. Separate s were determined for first-degree relatives (parents, siblings), grandparents, aunts and uncles, and all relatives combined. A total of 21% of participants could not provide complete information about diseases in their aunts and uncles. A sensitivity analysis was, therefore, performed using only firstdegree relatives and grandparents combined. A greater than 1 reflects an increased risk among relatives of patients with ALS compared to relatives of controls. The 95% confidence intervals (CI) for were obtained using the online calculator for CIs of relative risk (http://www.hutchon.net/ConfidRR.htm).
We fitted a linear mixed-effect model (maximum likelihood) using a binomial link function with ALS or not-ALS of the subjects included in the population-based study as outcome, and including affection status of family members as fixed effects and the family as unit of random effects, to account for the nonindependence of data obtained from individuals within the same family. 22 The advantage of this approach is that family size and number of affected individuals within families are also taken into account, instead of only having one affected family member as is the case with the calculations.
RESULTS
Informed consent to participate in the study was given by 762 (87%) of a total of 878 eligible patients identified between January 1, 2006, and May 31, 2009. Of the questionnaires sent to these 762 patients, 635 were returned (83%). Gender, mean age at onset, frequency of bulbar onset, and frequency of patients with FALS did not differ significantly between responders and nonresponders. A total of 1,905 population-based controls were selected from the GP's register, and 1,616 of these returned their questionnaire (response rate 85%). Table 2 shows the characteristics of the 635 patients and 1,616 controls included in the analyses. Cases and controls were similar for the matching variables, gender and age.
In this study, 41 patients (6.4%) had at least one family member with ALS and were, therefore, classified as having FALS, while the remainder (594 patients) were classified as having SALS. Relatives of patients have an elevated risk of ALS compared to controls ( any relative 2.42; 95% CI 1.65-3.57).
The occurrence of dementia was mildly increased only among parents and siblings of patients with SALS (1.32; 95% CI 1.10 -1.59), not among grandparents (0.98; 95% CI 0.79 -1.21) or aunts and uncles (0.95; 95% CI 0.79 -1.14). Among relatives of patients with FALS, occurrence of dementia was not increased (table 3) , although a (nonsignificant) increased frequency of dementia was found among parents and siblings (1.51; 95% CI 0.93-2.45) and among aunts and uncles (1.40; 95% CI 0.87-2.25), but not among grandparents (0.46; 95% CI 0.17-1.22).
A nonsignificant decrease of PD in all family members of patients with SALS combined was found (table 3) , although among first-degree relatives (1.12; 95% CI 0.78 -1.59) and among grandparents (1.23; 95% CI 0.66 -2.32) a mild increase was found. The increase of PD in family members of patients with FALS was also not significant (table 3) .
Vascular diseases were less frequently reported in relatives of both patients with SALS ( any relative 0.88; 95% CI 0.82-0.95) and patients with FALS ( any relative 0.73; 95% CI 0.57-0.94) compared with relatives of controls. Relatives were significantly less frequently diagnosed with MI (SALS: any relative 0.86; 95% CI 0.79 -0.94 and FALS: any relative 0.61; 95% CI 0.43-0.86). Stroke was also reported less frequently in relatives of patients. Probably due to a lower number of affected people than in MI, this difference was not significant (table 4) .
Sensitivity analysis, excluding aunts and uncles, showed similar results, except that the increased frequency of dementia among first-degree relatives and grandparents of patients with SALS combined was significant ( 1.16; 95% CI 1.01-1.33).
Using a linear mixed-effect model, we examined whether the number of affected relatives in families contributed to the results which were, however, similar to those presented in tables 3 and 4.
DISCUSSION
In this large, prospective, populationbased study, a mildly increased frequency of dementia was found only among first-degree relatives of patients with ALS. This increase, not present in other relatives, is substantially lower than that found in previous studies (table 1) . [7] [8] [9] The risk of PD in relatives of patients with ALS was not significantly increased, and, therefore, this study does not support the hypothesis of major shared genetic or environmental risk factors in the etiology of ALS, PD, and dementia. 23, 24 The risk of vascular diseases is lowered in relatives of both patients with SALS and patients with FALS, supporting the view that a beneficial vascular risk profile increases susceptibility for ALS. 12 The greatly increased risk of dementia and PD among family members of patients with ALS in previous studies led to the hypothesis that ALS is part of a continuum of neurodegenerative diseases. 7, 9 In the present study, the absolute risk of dementia among all family members was increased by only 0.4%, and by 1.2% among first-degree relatives in patients with SALS, and by 0.8% and 2.0% in patients with FALS.
The increased risk in relatives of patients with FALS may not reach statistical significance due to the relatively low number of patients. It is known that ALS and frontotemporal dementia (FTD) show familial aggregation, 25 and, therefore, the mildly increased risk of dementia among relatives of patients with ALS (in particular FALS) may largely be explained by the association between these 2 diseases. 26 Since identifying specific types of dementia by relatives is not reliable, we were not able to test this in the present study. 27 The specific association with FTD might be higher than the increased risk of dementia reported here, while an association between ALS and types of dementia other than FTD may be smaller.
Although a relatively large number of subjects participated in the present study, it cannot be excluded that the slightly increased risk of PD among first-degree relatives and grandparents of patients Abbreviations: ALS ϭ amyotrophic lateral sclerosis; CI ϭ confidence interval. with SALS did not reach significance because of insufficient power. The results do not, however, support a strong association between SALS and PD, in contrast to prior studies. 4, 7, 9 The variation in results between the present study and others on the family history of neurodegenerative diseases may be explained by differences in study design. Prior studies often had a relatively small study population, and a retrospective, hospital-based design. A hospital-based study design implies that only patients with ALS visiting the tertiary referral center are included, which introduces the risk of referral bias. 28 This occurs when the clinical features of patients presenting to a tertiary referral center differ from those in the community or general population. 29 It is plausible that patients with ALS with a positive family history are more likely to be referred to a tertiary referral center for diagnostic evaluation, information about heritability, or participation in research. In the hospital-based studies, this could have led to an overestimation of the occurrence of dementia and PD in families of patients with ALS. Furthermore, by using non-neurodegenerative neurologic controls in previous studies, patients with a positive family history of PD or dementia may have been selectively excluded, since dementia and PD show familial aggregation. 30, 31 This may have resulted in an underestimation of the occurrence of neurodegenerative diseases in families of controls. A populationbased study design, with the use of randomly selected population-based controls, is able to overcome these limitations. The single previous study meeting these criteria also failed to find an association with dementia and PD, but was not sufficiently powered to draw definitive conclusions. 8 The present relatively large, population-based study was able to give more accurate estimates of the risk of neurodegenerative diseases in families of both patients with ALS and controls, and therefore it provides evidence against the hypothesis that ALS shares major pathologic pathways with PD. Indeed, the latest combined international meta-analysis of genome-wide association studies (GWAS) on PD 32 shows several loci that have not been detected in the latest combined international analysis of GWAS in ALS. 33 Instead, the supplementary data of the genome-wide association study in FTD show a potential overlap with the ALS data on chromosome 9p21.2, although this still has to be established in a combined analysis. [33] [34] [35] The occurrence of vascular diseases is decreased in relatives of patients with ALS; this decrease was consistently present among relatives of both patients with SALS and patients with FALS and among firstdegree relatives, aunts and uncles, and grandparents. The decreased occurrence was caused by a lower fre-quency of MI as well as of stroke, although the latter decrease was not significant, probably due to the relatively few affected relatives. These findings suggest that a beneficial vascular risk profile is associated with an increased risk of ALS. This is the first study to investigate the familial aggregation of ALS with vascular diseases, and its results are congruent with several case-control studies that observed a lower frequency of vascular risk factors and diseases in patients with ALS. Hypertension, coronary artery disease, obesity, and cerebrovascular diseases occurred less frequently in patients with ALS than in control subjects in a population-based study in Rochester. 10 Others found that patients were more likely than controls to report they had always been slim, 13 and in a recent study it has been confirmed that patients with ALS have a lower premorbid BMI. 12 Studies on lipid levels in ALS have produced conflicting results, possibly due to differences in the control population. 11, 12, 36 Using population-based controls, a favorable lipid profile was found more frequently in ALS. 12 Hypolipidemia is associated with a shorter survival, which suggests that the vascular risk profile is also a disease-modifying factor. 11 In the SOD1 ALS mouse model, hypolipidemia is already present at the presymptomatic stage. 37 Only smoking, a probable risk factor in ALS, is inconsistent with the hypothesis that a beneficial vascular risk profile increases ALS susceptibility. 14 -18 The greater reduction in occurrence of MI than of stroke among relatives may suggest that vascular risk factors associated with MI have a greater effect on ALS susceptibility than those associated with stroke. In patients with MI, hypercholesterolemia, obesity, diabetes mellitus, and cigarette smoking are more prevalent than in patients with stroke, while hypertension, atrial fibrillation, and alcohol consumption are more frequent in patients with stroke. 38 A beneficial vascular risk profile may not itself have a causative role in the development of ALS, but it may be a marker for another factor that exerts a direct role in the etiology of ALS. A possible candidate for such a factor is physical activity. Since a 6-fold increased risk of ALS has been found in Italian professional football players, 39 there is an ongoing discussion about whether physical activity is a risk factor for ALS. A large well-designed populationbased study could answer this question, and the need for such a study is heightened by the present findings. The finding in SOD1 mice, though, that hypolipidemia is present in presymptomatic mice, supports that a beneficial vascular risk profile may be causative. 37 We acknowledge the limitations inherent in the use of a questionnaire study. Executive dysfunction and fatigability of patients with ALS may affect reliability of their answers in a questionnaire. Participants (both patients and controls) who returned questionnaires were, therefore, contacted to confirm and complete data. The average number of relatives with known disease status was equal between patients and controls, supporting that reliability was comparable between patients and controls in this study. Further, it was not possible to verify reported diagnoses. Since this probably applies equally to patients and controls, the likelihood of bias is reduced. Moreover, in a previous questionnaire study, certainty of the reported diagnoses could be checked and all were confirmed by the medical records. 7 However, the absence of a validation phase to the study remains a weakness. From our data it is not possible to know whether patients with ALS underreport or overreport the presence of other illnesses in their families. Verification from another source such as another independent relative should be included in future studies.
Since information about disease status in the present study was limited to first-degree relatives, grandparents, and aunts and uncles, and neurodegenerative diseases probably inherit as a complex disease, which does not fit simple inheritance patterns as with Mendelian diseases, it cannot be excluded that the present study was still underpowered to detect an increased frequency of neurodegenerative diseases.
A prospective study, including more types of relatives, and with verification of reported diagnoses using medical records or corroboration with other family members, may be needed to definitively determine whether neurodegenerative diseases aggregates within families.
Another limitation of the present study may have been that age of the family members was not available, and, thus, controlling for it was not possible. There is, however, no birth order effect in ALS, 40 and, therefore, it is likely that age of relatives is equally distributed among patients and controls.
The present study showed that familial aggregation of ALS with dementia is modest, and that there is a lack of familial aggregation with PD. Therefore, this study provides evidence that not all these neurodegenerative diseases share major pathophysiologic pathways, 24 but that the overlap with FTD requires further study. The lowered risk of vascular diseases in relatives of patients with ALS supports the view that a beneficial vascular risk profile is associated with increased susceptibility for ALS.
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